Severe infusion reaction due to nivolumab: A case report.

Seema KumariJames YunJames R SoaresPei N Ding

Published in: Cancer reports (Hoboken, N.J.) (2020)

Our knowledge and expertise with the use of immune checkpoint inhibitors are still evolving. This report highlights one of the rare possible side-effects that clinicians and patients may have to face with increasing indications and use of nivolumab in day to day practice.

Keyphrases

end stage renal disease
healthcare
ejection fraction
newly diagnosed
chronic kidney disease
primary care
low dose
prognostic factors
palliative care
peritoneal dialysis
early onset
patient reported outcomes
drug induced